A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma-Reference-Cited by-同舟云学术

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

Published:2020-11-19 Issue:1 Volume:87 Page:135-144
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Murray Stewart Tracy^ORCID,Von Hoff Daniel,Fitzgerald Michael,Marton Laurence J.,Becerra Carlos H. Roberto,Boyd Thomas E.,Conkling Paul R.,Garbo Lawrence E.,Jotte Robert M.,Richards Donald A.,Smith David A.,Stephenson Joe J.,Vogelzang Nicholas J.,Wu Hillary H.,Casero Robert A.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-020-04201-1.pdf

Reference37 articles.

1. Flynn AT, Hogarty MD (2018) Myc, oncogenic protein translation, and the role of polyamines. Med Sci (Basel) 6:2. https://doi.org/10.3390/medsci6020041

2. Casero RA Jr, Marton LJ (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6(5):373–390. https://doi.org/10.1038/nrd2243

3. Murray-Stewart TR, Woster PM, Casero RA Jr (2016) Targeting polyamine metabolism for cancer therapy and prevention. Biochem J 473(19):2937–2953. https://doi.org/10.1042/BCJ20160383